<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04734392</url>
  </required_header>
  <id_info>
    <org_study_id>01/2021</org_study_id>
    <nct_id>NCT04734392</nct_id>
  </id_info>
  <brief_title>Reducing Pacemaker Implantation After TAVR With Modified Implantation Technique</brief_title>
  <acronym>MIDAS - ULM</acronym>
  <official_title>Reducing Pacemaker Implantation After TAVR With Modified Implantation Technique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis of the study is that a modified and improved implantation protocol (regarding&#xD;
      membranous septum length and implantation depth) will decrease the need for permanent&#xD;
      pacemaker stimulation follow TAVR-procedures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Project objectives or hypothesis Hypothesis of the study is that a modified and improved&#xD;
      implantation protocol (regarding membranous septum length and implantation depth) will&#xD;
      decrease the need for permanent pacemaker stimulation following TAVR-procedures.&#xD;
&#xD;
      Patient profile and sample size The study cohort will comprise of patients referred to&#xD;
      transcatheter aortic valve replacement. Patients will be prospectively and consecutively&#xD;
      screened and enrolled at a tertiary high-volume center in Germany. TAVR will be performed&#xD;
      according to a modified implantation technique regarding membranous septum length. Pacemaker&#xD;
      rates will be analyzed and compared to a historical control. Taking into account a&#xD;
      contemporary pacemaker rate of 15%, a reduction to 7% will require a sample size of 239&#xD;
      patients per group to achieve statistically significance (Chi-squared test, alpha 0.05, beta&#xD;
      0.80).&#xD;
&#xD;
      Regarding the prospective cohort, interims analysis will be performed after each 10 TAVR&#xD;
      procedures. In case a signal towards worse outcomes with the modified implantation technique&#xD;
      will be observed, the institutional safety and endpoint adjudication committee will stop&#xD;
      further execution of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pacemaker implantation rate</measure>
    <time_frame>Day 5 after TAVR</time_frame>
    <description>Primary endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extent of paravalvular leak</measure>
    <time_frame>Day 5 after TAVR</time_frame>
    <description>Secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients alive</measure>
    <time_frame>30 days</time_frame>
    <description>Secondary endpoint</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>PM Implantation After TAVR</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <description>Historical cohort 2019 + 2020</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <description>Prospective study cohort 2020 + 2021 (TAVR implantation according new IFU)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TAVR</intervention_name>
    <description>TAVR implantation in cusp overlay technique</description>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study cohort will comprise of patients referred to transcatheter aortic valve&#xD;
        replacement. Patients will be prospectively and consecutively screened and enrolled at a&#xD;
        tertiary high-volume center in Germany.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients referred to TAVR procedure due to severe aortic stenosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  PM-implantation before TAVR&#xD;
&#xD;
          -  Valve-in-valve procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dominik Buckert, MD</last_name>
    <phone>0731500-0</phone>
    <email>dominik.buckert@uniklinik-ulm.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ulm University</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominik Buckert</last_name>
      <phone>07315000</phone>
      <email>dominik.buckert@uniklinik-ulm.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>January 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 2, 2021</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Dr. Dominik Buckert</investigator_full_name>
    <investigator_title>PD Dr. Dominik Buckert, MD</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

